Financial Services Forum

Seer to Present at the Canaccord MedTech, Diagnostics and Digital Health & Services Forum

Retrieved on: 
Friday, November 10, 2023
Proteomics, Financial Services Forum, Diagnosis, Seer, Digital health

REDWOOD CITY, Calif., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced company management will be participating in the upcoming Canaccord MedTech, Diagnostics and Digital Health and Services Forum in New York, NY.

Key Points: 
  • REDWOOD CITY, Calif., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced company management will be participating in the upcoming Canaccord MedTech, Diagnostics and Digital Health and Services Forum in New York, NY.
  • Seer’s management is scheduled to present on Thursday, November 16th at 1:00 p.m. Eastern Time / 10:00 a.m. Pacific Time.
  • A live webcast of the session will be available on the Investor section of Seer’s website at investor.seer.bio.
  • An archived replay will be available on the company’s website following the conference.

T2 Biosystems to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum

Retrieved on: 
Friday, November 3, 2023
Financial Services Forum, Diagnosis, Interest, Medtech, Digital health, Vaccine, Medical imaging

LEXINGTON, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced plans to participate in the upcoming Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum in New York, NY.

Key Points: 
  • LEXINGTON, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced plans to participate in the upcoming Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum in New York, NY.
  • Management is scheduled to present on Thursday, November 16, 2023, at 8:00am ET.
  • Interested parties may access a live and recorded webcast of the presentation on the “Investors” section of the Company’s website at www.t2biosystems.com .

Pulmonx to Participate at Upcoming Investor Conferences

Retrieved on: 
Tuesday, October 31, 2023
Canaccord Genuity, Diagnosis, Interest, Financial Services Forum, Digital health, Conference, Cryptocurrency

REDWOOD CITY, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in two upcoming investor conferences.

Key Points: 
  • REDWOOD CITY, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in two upcoming investor conferences.
  • Pulmonx management is scheduled to participate in a fireside chat at the Stifel 2023 Healthcare Conference in New York on Tuesday, November 14, 2023, at 11:25am PT / 2:25pm ET.
  • Interested parties may access a live and archived webcast of the event on the “Investors” section of the Pulmonx website at https://investors.pulmonx.com/ .
  • Pulmonx management will also be participating in investor meetings at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum in New York on Thursday, November 16, 2023.

Evolent to release third quarter financial results on Thursday, Nov. 2, 2023, and participate in upcoming investor conferences

Retrieved on: 
Tuesday, October 10, 2023
NYSE, EVH, EvoL, The Westin New York Grand Central Hotel, Stephens, Health, Financial Services Forum, Canaccord Genuity, Blackley, Piper Sandler Companies, Westin St. Francis, Lotte New York Palace Hotel, Digital health, Conference, Pharmaceutical industry

Shareholders and interested participants may listen to a live broadcast of the conference found on Evolent's investor relations website, ir.evolenthealth.com.

Key Points: 
  • Shareholders and interested participants may listen to a live broadcast of the conference found on Evolent's investor relations website, ir.evolenthealth.com.
  • An audio playback of the conference call will be available on Evolent's investor relations website for 90 days after the call.
  • Additionally, the company announced that Chief Executive Officer Seth Blackley, Chief Financial Officer John Johnson and Vice President, Investor Relations Seth Frank will participate in upcoming investor conferences.
  • Messrs. Johnson and Frank will present virtually at the BTIG Digital Health Forum on Monday, Nov. 20, 2023.

FICO Wins Innovators 2023 Award from Global Finance for Blockchain in AI Model Governance

Retrieved on: 
Thursday, July 20, 2023
Technology, Finance, Fintech, Banking, Professional Services, Blockchain, Software, Data Management, Artificial Intelligence, EU, Use, Financial services, Financial Services Forum, ML, Intelligence, Financial system, Organization, Development, Patent, AI, FICO, Fraud, Responsibility, Cryptocurrency, Medical device, Corinium Dobunnorum

FICO has been named one of The Innovators 2023 for its use of blockchain to manage and monitor AI development.

Key Points: 
  • FICO has been named one of The Innovators 2023 for its use of blockchain to manage and monitor AI development.
  • Developed and patented by FICO’s AI Innovation and Development team, Blockchain for AI Model Governance uses an immutable blockchain ledger that tracks end-to-end provenance of the development, operationalization and monitoring of ML models.
  • These are all tracked to an immutable blockchain to solidly demonstrate compliance with model development standards, compliance testing, and responsible AI.
  • The AI model governance blockchain enables auditable AI requirements to support governance, regulators, monitoring, and remedy of production issues.

The Ad Council's 69th Annual Public Service Award Dinner to honor Jamie Dimon, Chairman and Chief Executive Officer of JPMorgan Chase

Retrieved on: 
Thursday, July 13, 2023
Tufts University, JPMorgan Chase, Council, Small business, Advertising, Love, Partnership, Table, Financial Services Forum, Marketing, The Business Council, COVID-19, Ad Council, Smokey Bear, Public policy, MBA, Business, Multimedia, Business Roundtable, School, Bank Policy Institute, Partnership for New York City, Retirement, Hospital, Investment, Foreign policy, Harvard Business School, City, Glass house, Mental health, Safety, Bankruptcy, Cryptocurrency, Management, Verizon Communications

NEW YORK, July 13, 2023 /PRNewswire/ -- The Ad Council has announced that its 69th Public Service Award Dinner will honor Jamie Dimon, Chairman and Chief Executive Officer of JPMorgan Chase.

Key Points: 
  • NEW YORK, July 13, 2023 /PRNewswire/ -- The Ad Council has announced that its 69th Public Service Award Dinner will honor Jamie Dimon, Chairman and Chief Executive Officer of JPMorgan Chase.
  • The Ad Council has benefited incredibly from the support of JPMorgan Chase and we look forward to many more years of partnering together on the most pressing issues facing our country."
  • Jamie Dimon is Chairman of the Board and Chief Executive Officer of JPMorgan Chase, a global financial services firm with assets of $3.7 trillion and operations worldwide.
  • This year's event will be co-chaired by board members Carla Hassan (Chief Marketing Officer, JPMorgan Chase) and Diego Scotti (Chief Marketing Officer, Verizon).

PacBio to Present at Upcoming Investor Conferences

Retrieved on: 
Friday, November 11, 2022
Financial Services Forum, Digital health, Pacific Biosciences, NASDAQ, SBB, Microbiology, Technology, Research, Solution, Diagnosis, Conference, Infection, High fidelity

A webcast replay will be available for at least 30 days following the presentation.

Key Points: 
  • A webcast replay will be available for at least 30 days following the presentation.
  • Pacific Biosciences of California, Inc. (NASDAQ: PACB) is a premier life science technology company that is designing, developing and manufacturing advanced sequencing solutions to help scientists and clinical researchers resolve genetically complex problems.
  • Our products address solutions across a broad set of research applications including human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications.
  • For more information, please visit www.pacb.com and follow @PacBio.

Vericel to Participate in the Canaccord Genuity MedTech, Diagnostics, and Digital Health & Service Forum and the Stephens Annual Investment Conference

Retrieved on: 
Thursday, November 10, 2022
GLOBE, Financial Services Forum, Knee, Debridement, Sports medicine, Investor relations, CG, Webcast, NASDAQ, Digital health, CFO, Company, Conference, Chondrocyte, Patient, CEO, Thermal burn, Pharmaceutical industry, Diagnosis

CAMBRIDGE, Mass., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Company leadership will present at the upcoming Canaccord Genuity MedTech, Diagnostics, and Digital Health & Service Forum and the Stephens Annual Investment Conference.

Key Points: 
  • CAMBRIDGE, Mass., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Company leadership will present at the upcoming Canaccord Genuity MedTech, Diagnostics, and Digital Health & Service Forum and the Stephens Annual Investment Conference.
  • Nick Colangelo, President and CEO will present at the CG MedTech, Diagnostics, and Digital Health & Service Forum at 10:00 a.m.
  • ET at the Stephens Annual Investment Conference.
  • Webcasts of both presentations will be available on the Investor Relations section of the Vericel Corporation website at: http://investors.vcel.com .

T2 Biosystems to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum

Retrieved on: 
Wednesday, November 9, 2022
GLOBE, BioSystems, Medtech, Financial Services Forum, Health, Interest, NASDAQ, Digital health, Patient, Diagnosis, Medical imaging

LEXINGTON, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc.(NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced plans to participate in the upcoming Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum in New York, New York.

Key Points: 
  • LEXINGTON, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc.(NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced plans to participate in the upcoming Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum in New York, New York.
  • Management is scheduled to present on Thursday, November 17, 2022, at 2pm ET.
  • Interested parties may access a live and recorded webcast of the presentation on the Investors section of the Companys website at www.t2biosystems.com .
  • T2 Biosystems products include the T2Dx Instrument, the T2Bacteria Panel, the T2Candida Panel, the T2Resistance Panel, and the T2SARS-CoV-2 Panel and are powered by the proprietary T2 Magnetic Resonance (T2MR) technology.

InterVenn Biosciences to Participate in Canaccord Genuity’s MedTech, Diagnostics and Digital Health & Services Forum

Retrieved on: 
Thursday, November 10, 2022
Research, Technology, Genetics, Nanotechnology, Biotechnology, Health, Science, Oncology, Artificial Intelligence, Other Science, Canaccord Genuity, Financial Services Forum, Biology, Therapy, Digital health, History, Company, Diagnosis, Medical device

InterVenn Biosciences, a clinical technology company leveraging glycoproteomics to transform the future of healthcare, today announced Company management will present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum in New York on November 17, 2022 at 2:30 p.m. Eastern Time.

Key Points: 
  • InterVenn Biosciences, a clinical technology company leveraging glycoproteomics to transform the future of healthcare, today announced Company management will present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum in New York on November 17, 2022 at 2:30 p.m. Eastern Time.
  • The members of InterVenns executive leadership team will be available for one-on-one meetings at the event.
  • A live and archived webcast of the event will be available on the "For Investors" section of the InterVenn website at https://intervenn.com/investors/ following the forum.
  • InterVenn is a clinical technology company unlocking the value of glycoproteomics for the development of transformational healthcare solutions.